Terns Pharmaceuticals, Inc.
TERN
Hisse Senetlerindeki Sıralama
#3570
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Hisse Fiyatı
$52.95
Son senkronizasyon: 2026-05-15
Piyasa Değeri
$4.77B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
529.61%
Ülke
US
Ticaret Terns Pharmaceuticals, Inc. (TERN)
Kategori
Healthcare
Terns Pharmaceuticals, Inc. (TERN) için tedavüldeki hisse sayısı
December 2025 itibarıyla tedavüldeki hisse sayısı: 93.17M
Terns Pharmaceuticals, Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 93.17M'dir. December 2023 sonunda şirketin 71.26M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
Terns Pharmaceuticals, Inc. (TERN) için 2018 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 93.17M | 17.18% |
| 2024 | 79.51M | 11.57% |
| 2023 | 71.26M | 97.76% |
| 2022 | 36.03M | 42.60% |
| 2021 | 25.27M | 0.57% |
| 2020 | 25.13M | 0.11% |
| 2019 | 25.10M | 4.69% |
| 2018 | 23.97M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | 172.52% |
US
|
|
| 396.00M | 325.05% |
US
|
|
| 478.91M | 414.04% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -33.25% |
NL
|
